Harrow Health Overview
- Harrow Health, Inc. is a publicly traded pharmaceutical company (Nasdaq:HROW) based in Nashville, TN.
- Harrow Health started six healthcare businesses since 2014, including ImprimisRx, Eton Pharmaceuticals, Surface Pharmaceuticals, and Melt Pharmaceuticals.
- Harrow Health hired Drew Livingston as its Chief Innovation Officer in 2019.
- Harrow Health's subsidiary, Visionology.com, focuses on telemedicine.
- Harrow Health is known for its advocacy for drug pricing and patient access to affordable medication.
Administration and Drug Pricing Advocacy
- Mark L. Baum is the founder and CEO of Harrow Health, with a background in law.
- Baum has been working in the HIV-related pharmacy field since 1999.
- Baum has been an advocate for drug pricing and patient advocacy, including debating former US congressman James Greenwood on this issue.
- Harrow Health, through its ImprimisRx subsidiary, aims to create competition for monopolized drugs by marketing new formulations as a compounding pharmacy.
- Harrow Health gained attention for offering low-cost alternatives to expensive medications, such as a $1 per pill alternative to Daraprim.
ImprimisRx Compounding Business
- ImprimisRx is Harrow Health's compounding subsidiary.
- ImprimisRx was the first compounding company to offer cGMP ophthalmic eye drops and other sterile compounded products at a national scale.
- ImprimisRx's primary business is compounding drugs to market them to specific populations.
- ImprimisRx focuses on developing and selling inexpensive alternatives to off-patent medicines.
- ImprimisRx expanded its business to include the sale of FDA-approved steroid product called Dexycu through a partnership with EyePoint Pharmaceuticals.
Litigation
- Harrow Health (then Imprimis Pharmaceuticals) faced a lawsuit from Allergan for alleged false and misleading marketing statements.
- Allergan was accused of engaging in significant lobbying to complain about ImprimisRx.
- In 2017, ImprimisRx received a warning letter from the FDA regarding false or misleading claims about efficacy and risks in their eye drops.
- After a jury trial, Harrow was ordered to pay $0 for disgorgement of profit and $48,500 for lost profit, despite Allergan seeking $60 million.
- The lawsuit highlighted the power dynamics between a small pharmaceutical company like Imprimis and a large company like Allergan.
External Links and References
- Harrow Health's accomplishments and activities have been covered by various news outlets, including The Wall Street Journal, Forbes, and USA TODAY.
- ImprimisRx's low-cost alternatives to expensive drugs gained international attention.
- Harrow Health's CEO, Mark L. Baum, has written about drug pricing and monopolies in his monograph and has spoken at the Oxford Union debating society.
- Harrow Health's subsidiaries, Eton Pharmaceuticals and Surface Pharmaceuticals, have received significant funding for their operations.
- Harrow Health's Visionology.com subsidiary focuses on telemedicine and improving access to healthcare services.
Harrow Health, formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company (Nasdaq: HROW) based in Nashville, TN.
| Formerly | Imprimis Pharmaceuticals ( - Jan 2019) |
|---|---|
| Type | Public |
| Nasdaq: HROW Russell Microcap Index component | |
| Industry | Pharmaceutical Industry |
| Founded | 2012 |
| Headquarters | Nashville, TN , United States |
Number of locations | 1 (Nashville, TN) |
Key people |
|
| Products | Pharmaceuticals |
| Subsidiaries |
|
| Website | www |
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its Chief Innovation Officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary.
